Use of alpha-1-antitrypsin for the preparation of drugs for the treatment of chronic fatigue syndrome
View Patent ↗The present invention relates to the use of alpha-1-antitrypsin for the preparation of effective drugs for the treatment of chronic fatigue syndrome. In addition, the present invention relates to the use of plasma or other therapeutic forms with an alpha-1-antitrypsin content sufficient to obtain a dose of 6 mg or more of alpha-1-antitrypsin per kg of body weight at a frequency of between 1 and 31 days.
1. A method for treating cognitive impairment in a patient suffering from chronic fatigue syndrome comprising administering to said patient alpha-1-antitrypsin at a dose sufficient to reduce said cognitive impairment.
2. The method of claim 1 , wherein the dose of alpha-1-antitrypsin is sufficient to reduce the ratio of 83 kDa RNase L to 37 kDa RNase L below 0.5 as measured in peripheral blood mononuclear cells from said patient.
3. The method of claim 1 , wherein administering to said patient alpha-1-antitrypsin at a dose sufficient to reduce said cognitive impairment comprises administering to said patient alpha-1-antitrypsin at a dose greater than 6 mg/kg patient body weight.
4. The method of claim 3 , wherein the dose of alpha-1-antitrypsin administered to said patient is 15-360 mg/kg patient body weight.
5. The method of claim 3 , wherein administration of the dose of alpha-1-antitrypsin is repeated at least once at a frequency between 1 and 31 days.
6. The method of claim 1 , wherein the alpha-1-antitrypsin is administered at a dose sufficient to achieve a level of alpha-1-antitrypsin in serum of the patient up to eight times higher than base levels, 24 hours after administration.
7. The method of claim 1 , wherein administering to said patient alpha-1-antitrypsin at a dose sufficient to reduce said cognitive impairment comprises administering to said patient alpha-1-antitrypsin at a dose ranging from 25 to 60 mg/kg patient body weight, and the dose is repeated at least once at a frequency of 1 week.
8. The method of claim 1 , wherein administering to said patient alpha-1-antitrypsin is performed by a route selected from the group consisting of: parenterally, intravenously, intramuscularly, intradermally, and inhalation.
9. The method of claim 1 , wherein administering to said patient alpha-1-antitrypsin at a dose sufficient to reduce said cognitive impairment comprises administering to said patient alpha-1-antitrypsin at a dose ranging from 25 to 60 mg/kg patient body weight, and the dose is repeated at least once at a frequency of 1 week for a period of 8 weeks.